Shares of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) were up 3.6% during mid-day trading on Wednesday . The company traded as high as $41.90 and last traded at $41.50, with a volume of 235,556 shares traded. The stock had previously closed at $40.06.

A number of analysts have recently issued reports on AGIO shares. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a report on Sunday, March 27th. SunTrust Banks Inc. started coverage on shares of Agios Pharmaceuticals in a report on Tuesday, March 29th. They set a “buy” rating and a $57.00 price objective for the company. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a report on Thursday, March 31st. Zacks Investment Research raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a report on Wednesday, April 20th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $50.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, May 18th. Six equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Agios Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $69.67.

The stock’s 50-day moving average price is $47.31 and its 200-day moving average price is $45.75. The stock’s market cap is $1.63 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.79) by $0.18. During the same period last year, the company earned ($0.13) earnings per share. The firm earned $31.30 million during the quarter, compared to analysts’ expectations of $20.94 million. The business’s revenue for the quarter was down 8.5% on a year-over-year basis. On average, equities analysts expect that Agios Pharmaceuticals Inc. will post ($3.46) EPS for the current fiscal year.

In related news, Director Lewis Clayton Jr. Cantley sold 627 shares of the company’s stock in a transaction on Monday, June 27th. The shares were sold at an average price of $40.37, for a total transaction of $25,311.99. Following the completion of the transaction, the director now owns 125,921 shares in the company, valued at $5,083,430.77. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Scott Biller sold 27,500 shares of the company’s stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $65.00, for a total transaction of $1,787,500.00. Following the transaction, the insider now owns 81,376 shares of the company’s stock, valued at approximately $5,289,440. The disclosure for this sale can be found here.

Other institutional investors have added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System raised its position in Agios Pharmaceuticals by 7.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 22,672 shares of the biopharmaceutical company’s stock valued at $1,472,000 after buying an additional 1,624 shares during the period. Rhumbline Advisers raised its position in Agios Pharmaceuticals by 2.5% in the fourth quarter. Rhumbline Advisers now owns 24,947 shares of the biopharmaceutical company’s stock valued at $1,620,000 after buying an additional 605 shares during the period. ProShare Advisors LLC raised its position in Agios Pharmaceuticals by 5.9% in the fourth quarter. ProShare Advisors LLC now owns 31,258 shares of the biopharmaceutical company’s stock valued at $2,029,000 after buying an additional 1,740 shares during the period. GAM Holding AG raised its position in Agios Pharmaceuticals by 210.9% in the fourth quarter. GAM Holding AG now owns 45,700 shares of the biopharmaceutical company’s stock valued at $2,967,000 after buying an additional 31,000 shares during the period. Finally, Mutual of America Capital Management LLC raised its position in Agios Pharmaceuticals by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 17,325 shares of the biopharmaceutical company’s stock valued at $1,125,000 after buying an additional 86 shares during the period.

Agios Pharmaceuticals, Inc (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.